164 related articles for article (PubMed ID: 25931164)
1. In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2: From Genotype to Phenotype.
Heineman TE; Evans DG; Campagne F; Selesnick SH
Otol Neurotol; 2015 Jun; 36(5):908-14. PubMed ID: 25931164
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A; Jones A; Joe H; Heap L; Smith MJ; Wallace AJ; Halliday D; Parry A; Taylor A; Raymond L; Shaw A; Afridi S; Obholzer R; Axon P; King AT; ; Friedman JM; Evans DG
J Med Genet; 2015 Oct; 52(10):699-705. PubMed ID: 26275417
[TBL] [Abstract][Full Text] [Related]
3. Further genotype--phenotype correlations in neurofibromatosis 2.
Selvanathan SK; Shenton A; Ferner R; Wallace AJ; Huson SM; Ramsden RT; Evans DG
Clin Genet; 2010 Feb; 77(2):163-70. PubMed ID: 19968670
[TBL] [Abstract][Full Text] [Related]
4. Prediction and evaluation of deleterious and disease causing non-synonymous SNPs (nsSNPs) in human NF2 gene responsible for neurofibromatosis type 2 (NF2).
Havranek B; Islam SM
J Biomol Struct Dyn; 2021 Nov; 39(18):7044-7055. PubMed ID: 32787631
[TBL] [Abstract][Full Text] [Related]
5. [Phenotype-genotype study in 154 French NF2 mutation carriers].
Demange L; De Moncuit C; Thomas G; Olschwang S
Rev Neurol (Paris); 2007 Nov; 163(11):1031-8. PubMed ID: 18033041
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis 2 phenotypes and germ-line NF2 mutations determined by an RNA mismatch method and loss of heterozygosity analysis in NF2 schwannomas.
Hung G; Faudoa R; Baser ME; Xue Z; Kluwe L; Slattery W; Brackman D; Lim D
Cancer Genet Cytogenet; 2000 Apr; 118(2):167-8. PubMed ID: 10748301
[TBL] [Abstract][Full Text] [Related]
7. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes.
Kluwe L; Bayer S; Baser ME; Hazim W; Haase W; Fünsterer C; Mautner VF
Hum Genet; 1996 Nov; 98(5):534-8. PubMed ID: 8882871
[TBL] [Abstract][Full Text] [Related]
8. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.
Ruttledge MH; Andermann AA; Phelan CM; Claudio JO; Han FY; Chretien N; Rangaratnam S; MacCollin M; Short P; Parry D; Michels V; Riccardi VM; Weksberg R; Kitamura K; Bradburn JM; Hall BD; Propping P; Rouleau GA
Am J Hum Genet; 1996 Aug; 59(2):331-42. PubMed ID: 8755919
[TBL] [Abstract][Full Text] [Related]
9. A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes.
Scoles DR; Baser ME; Pulst SM
Neurology; 1996 Aug; 47(2):544-6. PubMed ID: 8757035
[TBL] [Abstract][Full Text] [Related]
10. Defects in neurofibromatosis 2 protein function can arise at multiple levels.
Gutmann DH; Geist RT; Xu Hm; Kim JS; Saporito-Irwin S
Hum Mol Genet; 1998 Mar; 7(3):335-45. PubMed ID: 9466988
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
Gutmann DH; Hirbe AC; Haipek CA
Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.
Kluwe L; MacCollin M; Tatagiba M; Thomas S; Hazim W; Haase W; Mautner VF
Am J Med Genet; 1998 May; 77(3):228-33. PubMed ID: 9605590
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.
Stokowski RP; Cox DR
Am J Hum Genet; 2000 Mar; 66(3):873-91. PubMed ID: 10712203
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
Baser ME; Rai H; Wallace AJ; Evans DG
Fam Cancer; 2005; 4(4):321-2. PubMed ID: 16341811
[TBL] [Abstract][Full Text] [Related]
15. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.
Evans DG; Trueman L; Wallace A; Collins S; Strachan T
J Med Genet; 1998 Jun; 35(6):450-5. PubMed ID: 9643284
[TBL] [Abstract][Full Text] [Related]
16. CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor.
MacCollin M
Brain Dev; 1995; 17(4):231-8. PubMed ID: 7503383
[TBL] [Abstract][Full Text] [Related]
17. Mosaicism in sporadic neurofibromatosis 2 patients.
Kluwe L; Mautner VF
Hum Mol Genet; 1998 Dec; 7(13):2051-5. PubMed ID: 9817921
[TBL] [Abstract][Full Text] [Related]
18. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
[TBL] [Abstract][Full Text] [Related]
19. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.
Baser ME; Kuramoto L; Joe H; Friedman JM; Wallace AJ; Gillespie JE; Ramsden RT; Evans DG
Am J Hum Genet; 2004 Aug; 75(2):231-9. PubMed ID: 15190457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
